May 24, 2012 |
|
In 2009, there were 58,663 drug-related ED visits involving children aged 12 to 14, and about half (28,068 visits, or 48 percent) involved misuse or abuse of drugs (Figure 1). Girls aged 12 to 14 made three fifths (58 percent) of the visits for misuse or abuse. In this age group, about one tenth (9 percent) of these ED visits involved patients aged 12, one quarter (26 percent) involved those aged 13, and nearly two thirds (65 percent) involved those aged 14.
Visits | Percent |
---|---|
Other Drug Involvement* | 52% |
Misuse or Abuse of Drugs | 48% |
Girls | 58% |
Boys | 42% |
* Includes accidental ingestions, adverse reactions, and suicide attempts. Source: 2009 data from 2010 SAMHSA Drug Abuse Warning Network (DAWN). |
Prescription and over-the-counter medications were involved in half (50 percent) of ED visits for misuse or abuse of drugs by children aged 12 to 14 (Table 1). Pain relievers were involved in 14 percent, including those containing acetaminophen (7 percent) or ibuprofen (5 percent). Anti-anxiety and insomnia drugs (e.g., Xanax®, clonazepam) were involved in 11 percent of visits, and central nervous system stimulants (e.g., Adderall®, Ritalin®) were involved in 4 percent. Table 1 describes other drugs that contributed to ED visits in this age group. Medication involvement overall was more likely among girls than boys (55 vs. 42 percent) (Figure 2).
Drug Category | Number of ED Visits: Total |
Percent of ED Visits: Total |
Number of ED Visits: Boys |
Percent of ED Visits: Boys |
Number of ED Visits: Girls |
Percent of ED Visits: Girls |
---|---|---|---|---|---|---|
Total ED Visits | 28,068 | 100% | 11,817 | 100% | 16,250 | 100% |
Medications | 13,927 | 50% | 5,015 | 42% | 8,912 | 55% |
Pain Relievers | 3,979 | 14% | 712 | 6% | 3,267 | 20% |
Acetaminophen Products | 1,859 | 7% | ** | ** | 1,687 | 10% |
Ibuprofen Products | 1,273 | 5% | ** | ** | 1,093 | 7% |
Narcotic Pain Relievers | 484 | 2% | ** | ** | ** | ** |
Anti-anxiety and Insomnia Drugs | 3,200 | 11% | 1,591 | 13% | 1,609 | 10% |
Benzodiazepines | 2,542 | 9% | ** | ** | 1,142 | 7% |
Antidepressants | 1,723 | 6% | ** | ** | 1,291 | 8% |
Central Nervous System Stimulants | 1,011 | 4% | 797 | 7% | 214 | 1% |
Respiratory System Medications | 1,533 | 5% | ** | ** | 1,102 | 7% |
Illicit Drugs | 7,813 | 28% | 4,726 | 40% | 3,087 | 19% |
Marijuana | 6,305 | 22% | 3,928 | 33% | 2,377 | 15% |
Alcohol | 10,427 | 37% | 3,996 | 34% | 6,431 | 40% |
* Because multiple drugs may be involved in each visit, estimates of visits by drug may add to more than the total, and percentages may add to more than 100 percent. ** Estimate suppressed due to low statistical precision. Source: 2009 data from 2010 SAMHSA Drug Abuse Warning Network (DAWN). |
Selected Drugs | Boys | Girls |
---|---|---|
Medications* | 42% | 55% |
Alcohol | 34% | 40% |
Illicit Drugs* | 40% | 19% |
Marijuana* | 33% | 15% |
* The difference between boys and girls was statistically significant at the .05 level. Source: 2009 data from 2010 SAMHSA Drug Abuse Warning Network (DAWN). |
Illicit drugs were involved in 28 percent of visits for misuse or abuse of drugs by children aged 12 to 14, much of which was accounted for by visits involving marijuana (22 percent). Visits by boys were more likely than visits by girls to involve illicit drugs (40 vs. 19 percent); 33 percent of visits by boys involved marijuana compared with 15 percent of visits by girls. Alcohol was involved in 37 percent of ED visits, with similar proportions for boys and girls (34 and 40 percent, respectively).
The majority of ED visits for misuse or abuse of drugs by children aged 12 to 14 (86 percent) involved a single drug type (alcohol only, illicit drugs only, or medications only). The remaining 14 percent of drug misuse or abuse ED visits by children aged 12 to 14 involved drugs in combination, much of which was accounted for by visits involving alcohol in combination (11 percent) (Figure 3).
Drugs | Percent |
---|---|
Medications Only | 41% |
Alcohol Only | 26% |
Illicit Only | 20% |
Marijuana Only | 14% |
Other Illicit Drug Only | 6% |
Multiple Drugs | 14% |
Alcohol in Combination* | 11% |
Other Drug Combinations | 3% |
* Alcohol in any combination with medications and/or illicit drugs. Source: 2009 data from 2010 SAMHSA Drug Abuse Warning Network (DAWN). |
Substance use, related ED visits, and admission to substance use treatment programs among children aged 12 to 14, although they occur on a relatively small scale, are disturbing occurrences. Despite legal restrictions, children can gain access to a variety of drugs and alcohol. Although there is ample research that supports the adverse effects of drugs on the developing child, youths frequently lack the developmental maturity to understand and act on knowledge about the risks involved. Parents and other adults should monitor and prevent access to these drugs in the home. Girls aged 12 to 14 are of particular concern because they made a higher proportion of visits overall. However, visits by boys were more likely to involve illicit drugs, especially marijuana; thus, prevention activities to reduce illicit drug use in this group are important.
Early education and prevention programs concerning substance use are important, and a number of approaches have been developed.8,9 The findings in this report support the importance of addressing the dangers of nonmedical use of medications, in addition to alcohol and illicit drug use, as part of the drug use prevention curriculum.
Primary care providers can also play an important role in reducing the number of children aged 12 to 14 who are seen in the ED for drug-related medical emergencies. The American Academy of Pediatrics recommends that all adolescents be screened for alcohol, tobacco, and other drug use at every office visit, and practical and validated screening methods are available.10,11 Resources have been developed to help parents and others have open and direct conversations about the dangers of drug and alcohol use with their children.12,13 When appropriate, ED staff can refer patients to substance abuse treatment programs that are designed to meet the unique needs of these emerging young adolescents.14
The Drug Abuse Warning Network (DAWN) is a public health surveillance system that monitors drug-related morbidity and mortality. DAWN uses a probability sample of hospitals to produce estimates of drug-related emergency department (ED) visits for the United States and selected metropolitan areas annually. DAWN also produces annual profiles of drug-related deaths reviewed by medical examiners or coroners in selected metropolitan areas and States.
Any ED visit related to recent drug use is included in DAWN. All types of drugs—licit and illicit—are covered. Alcohol involvement is documented for patients of all ages if it occurs with another drug. Alcohol is considered an illicit drug for minors and is documented even if no other drug is involved. The classification of drugs used in DAWN is derived from the Multum Lexicon, copyright 2010 Lexi-Comp, Inc. and/or Cerner Multum, Inc. The Multum Licensing Agreement governing use of the Lexicon can be found at http://www.samhsa.gov/data/DAWN.aspx. DAWN is one of three major surveys conducted by the Substance Abuse and Mental Health Services Administration's Center for Behavioral Health Statistics and Quality (SAMHSA/CBHSQ). For more information on other CBHSQ surveys, go to http://www.samhsa.gov/data. SAMHSA has contracts with Westat (Rockville, MD) and RTI International (Research Triangle Park, NC) to operate the DAWN system and produce publications. For publications and additional information about DAWN, go to http://www.samhsa.gov/data/DAWN.aspx. |
The DAWN Report is published periodically by the Center for Behavioral Health Statistics and Quality (formerly the Office of Applied Studies), Substance Abuse and Mental Health Services Administration (SAMHSA). All material appearing in this report is in the public domain and may be reproduced or copied without permission from SAMHSA. Additional copies of this report or other reports from the Center for Behavioral Health Statistics and Quality are available online: http://www.samhsa.gov/data/. Citation of the source is appreciated. For questions about this report, please e-mail: shortreports@samhsa.hhs.gov.
DAWN_058 |
This page was last updated on October 11, 2010. |